In fact, the National Comprehensive Cancer Network guideline as of this writing states that panels are “intended for individuals who have tested negative for high penetrance genes (e.g., BRCA1/2) and for those whose family history is suggestive of more than one syndrome,”23 but the inclusion of BRCA1 and BRCA2 in hereditary cancer panels does not increase the cost, lending itself to a more comprehensive and cost-effective method for evaluating patients for hereditary cancer predisposition. The gene discussed is BRCA1; the disease is cancer.